Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature

Critical Reviews in Oncology/Hematology

Volumn 91, Issue 1, 2014, Pages 1-8

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Chemotherapy; Combined treatment; Hepatocellular carcinoma; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PR 104; RAPAMYCIN; SORAFENIB; UFT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; NAUSEA; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SKIN TOXICITY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84901607868     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.12.013     Document Type: Review

References (22)

1. Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst 2013, 25(December (4)):165-171. [Epub 2013 Sep 21]. 10.1016/j.jnci.2013.08.002.
2. White D., Firoz A., Elserag H. Epidemiology of hepatocellular carcinoma. Hepatocellular carcinoma. Diagnosis and treatment 2010, Humana Press, http://www.lbin.com/online/humanapress.html.
3. Abdel-Rahman O. Exploring systemic options for advanced hepatocellular carcinoma 2013, Lambert Academic Publishing (LAP), https://www.lap-publishing.com, ISBN-13:978-3-659-43013-8. 1st ed.
4. Wang Z.G., Zhang G.F., Wu J.C. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov Ther 2013, 7(August (4)):137-143.
5. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(February (2)):429-442.
6. Abdel-Rahman O., Elsayed Z.A. Combination Trans Arterial Chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig Dis Sci 2013, 58(December (12)):3389-3396. [Epub 2013 Sep 18]. 10.1007/s10620-013-2872-x.
7. Bruix J., Sherman M., Llovet J.M. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35(September (3)):421-430.
8. Llovet J.M., Ricci S., Mazzaferro V. Sorafenib for advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
9. Cheng A.L., Kang Y.K., Chen Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(January (1)):25-34. [Epub 2008 December 16]. 10.1016/S1470-2045(08)70285-7.
10. Abdel-Rahman O., Abdelwahab M., Shaker M., Abdelwahab S., Elbassiony M., Ellithy M., et al. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. J Egypt Natl Cancer Inst 2013, (in press, corrected proof). 10.1016/j.jnci.2013.08.003.
11. Gomez-Martin C., Bustamante J., Castroagudin J.F. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012, 18:45-52.
12. Abou-Alfa G.K., Johnson P., Knox J.J. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma. J Am Med Assoc 2010, 304(19):2154-2160.
13. Hsu C.H., Shen Y.C., Lin Z.Z. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010, 10.1016/j.jhep.2010.01.035.
14. Petrini I., Lencioni M., Ricasoli M. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2012, 69:773-780.
15. Prete S.D., Montella L., Caraglia M. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010, 66:837-844.
16. Lee S.J., Lee J., Park S.H. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs 2012, 30:1540-1547.
17. Abou-Alfa G.K., Chan S.L., Lin C.C. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011, 68:539-545.
18. Richlya H., Schultheisb B., Adamietzc I.A. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 2009, 45:579-587.
19. Cheng A., Kang Y., Lin D. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011, 29(Suppl.). [abstr 4000].
20. Abdel-Rahman O., Abdelwahab M., Shaker M., Abdelwahab S., Elbassiony M., Ellithy M., et al. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013, 30(September (3)):655. [Epub 2013 July 4]. 10.1007/s12032-013-0655-z.
21. Llovet J.M., Di Bisceglie A.M., Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100(May (10)):698-711. [Epub 2008 May 13]. 10.1093/jnci/djn134.
22. Finn R.S., Poon R.T., Yau T. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013, (August). pii: S0168-8278(13)00544-8. 10.1016/j.jhep.2013.07.029.